NYXH NASDAQ
Nyxoah S.A.
1W: -6.2%
1M: -9.9%
3M: -23.2%
YTD: -69.8%
1Y: -72.5%
3Y: -80.8%
5Y: -95.6%
$1.36
+0.03 (+2.26%)
Weekly Expected Move ±13.5%
$1
$1
$1
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$136.1M
52W Range1.26-6.875
Volume68,516
Avg Volume354,393
Beta0.96
Dividend—
Analyst Ratings
Company Info
CEOOlivier Taelman
Employees154
SectorHealthcare
IndustryMedical - Specialties
IPO Date2021-04-28
Websitenyxoah.com
Rue Edouard Belin 12
Mont-Saint-Guibert, WA 1435
BE
Mont-Saint-Guibert, WA 1435
BE
32 1 022 23 55
About Nyxoah S.A.
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The companyâs lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Recent Insider Trades
No insider trades found